ПЛАЗМА АЛДОСТЕРОН ВА РЕНИН ФАОЛИЯТИГА БАРАЛИ ГИПЕРТАНСИЯ ВАРИАНТЛАРИ ХУСУСИЯТЛАРИ
##article.subject##:
гипертония, патогенез, ренин-ангиотензин-алдостерон тизими##article.abstract##
Аниқланишича, гипертония билан оғриган беморларда иккита тур аниқланган - ўртача плазма ренин фаоллиги билан тез-тез учрайдиган ҳажмга боғлиқ ва камроқ тез-тез ренинга боғлиқ. Ҳажмига боғлиқ бўлган гипертензия кекса ёшдаги ва клиник ва кундалик қон босимининг юқори даражаси билан, ренинга боғлиқ гипертензия юқори тана массаси индекси ва метаболик касалликлар билан боғлиқ.
Библиографические ссылки
Paul M., Mehr A.P., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2016; 86 (3): 747-803.
Sealey J.E., Parra D., Rosenstein R., Laragh J.H. "Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension. 2010; 55 (3): е16.
Furberg C.D. Renin-guided treatment of hypertension: time for action. Am. J. Hypertens. 2020; 23 (9): 929-30.
Walmor C. DeMello, Edward D. Frohlich. Renin Angiotensin System and Cardiovascular Disease. USA: Humana press; 2019; 27: 35-59.
Leung P.S. The peptide hormone angiotensin II: its new functions in tissues and organs. Curr. Protein Pept. Sci. 2014; 5: 267-73.
Laragh J.H. Laragh’s Lessons in Renin System Pathophysiology for Treating Hypertension and its Fatal Cardiovascular Consequences. New York: Elsevier Science; 2012.
Laragh J.H., Sealey J.E. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am. J. Hypertens. 2011; 24 (11): 1164-80.
Furberg C.D. Renin test-guided drug treatment of hypertension: the need for clinical trials. Am. J. Hypertens. 2011; 24 (11): 1158-63.
Castrop H., Höcherl K., Kurtz A., Schweda F., Todorov V., Wagner C. Physiology of kidney renin. Physiol. Rev. 2010; 90 (2): 607-73.
Furberg C.D. Treatment of hypertension: a failing report card. Am. J. Hypertens. 2009; 22 (1): 1-2.
Laragh J., Sealey J.E. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance forб correctly treating hypertension and for evaluating ALLHAT. Am. J. Hypertens. 2013; 16 (5, Pt. 1): 407-15.
Obarzanek E., Proschan M.A., Vollmer W.M., Moore T.J., Sacks F.M., Appel L.J. et al. Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension. 2013; 42 (4): 459-67.
Kravtsova O.A. The Value of Plasma Renin Activity Profi ling and Optimization of the Treatment of Hypertension: Diss. Moscow; 2014. (in Russian)
Sim J.J., Bhandari S.K., Shi J., Kalantar-Zadeh K., Rasgon S.A., Sealey J.E. et al. Plasma renin activity (PRA) levels and antihyper-tensive drug use in a large healthcare system. Am. J. Hypertens. 2021; 25 (3): 379-88.
Kotovskaya Yu.V., Kravtsova O.A., Pavlova E.A. Determination of plasma renin activity as a strategy for selecting and changing antihypertensive therapy. Arterial'naya gipertenziya. 2013; 19 (5): 380-388. (in Russian)
Gonzalez M.C., Cohen H.W., Sealey J.E., Laragh J.H., Alderman M.H. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am. J. Hypertens. 2011; 24 (11): 1181-1186.
